China says talks to include Paxlovid in its health insurance drug list fail

  • 📰 STForeignDesk
  • ⏱ Reading Time:
  • 37 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 18%
  • Publisher: 71%

Health Health Headlines News

The antiviral drug is currently covered by China's broad healthcare insurance scheme under temporary measures. Read more at straitstimes.com.

BEIJING - China will not include Pfizer Inc’s Paxlovid in an update to its list of medicines covered by basic medical insurance schemes as the US firm quoted a high price for the Covid-19 drug, China’s Healthcare Security Administration said on Sunday.

Inclusion on the list means a drug is accessible via state insurance schemes, which will boost volumes but comes with the condition that manufacturers lower prices. Past rounds have seen drugmakers cut prices by as much as 62 per cent after negotiations with officials.The NHSA said Paxlovid would continue to be eligible to be paid for by state medical insurance until the current planned end-date to the temporary measures of March 31.

The sudden loosening of restrictions has fueled a giant wave of infections and prompted many to turn to underground channels to procure remedies such as Paxlovid, which a clinical trial has found to have reduced hospitalisations in high-risk patients by around 90 per cent.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

Lol Pfizer sucks

straits_times Not surprising why it failed.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 4. in HEALTH

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

China in talks with Pfizer for generic Covid-19 drug: SourcesHONG KONG/BEIJING – China is in talks with Pfizer Inc to secure a licence that will allow domestic drugmakers to manufacture and distribute a generic version of the US firm's Covid-19 antiviral drug Paxlovid in China, three sources told Reuters. China's medical products regulator – the National Medical Products Administration (NMPA) – has been leading the talks with Pfizer since...
Source: asiaonecom - 🏆 10. / 59 Read more »